SCHEMBL4672052

SCHEMBL4672052

O=C(O)C(O)=CC(=O)c1occc1S(=O)(=O)c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.37
TSHR P16473 1/20 0.37
HTT P42858 1/20 0.37
HTR6 P50406 6/20 0.36
GAA P10253 3/20 0.36
POLB P06746 1/20 0.36
GFER P55789 1/20 0.36
ALDH1A1 P00352 4/20 0.35
MAPT P10636 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
KDM4E B2RXH2 2/20 0.33
KMT2A Q03164 1/20 0.33
ATM Q13315 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
ERAP1 Q9NZ08 1/20 0.32
PKM P14618 1/20 0.32
HPGD P15428 1/20 0.32
MMP1 P03956 1/20 0.32
MMP2 P08253 1/20 0.32
MMP3 P08254 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673417 1.00 NPSR1 (0.37) NPSR1TSHRHTTHTR6GAA
SCHEMBL4674294 0.88 ALDH1A1 (0.39) POLBALDH1A1MAPTKDM4EKMT2A
SCHEMBL4678323 0.88 MMP1 (0.38) NPSR1MAPTKDM4EMMP1MMP2
SCHEMBL4674289 0.88 ALDH1A1 (0.39) POLBALDH1A1MAPTKDM4EKMT2A
SCHEMBL4678326 0.88 MMP1 (0.38) NPSR1MAPTKDM4EMMP1MMP2
SCHEMBL6470461 0.80 NPSR1 (0.47) NPSR1TSHRHTTHTR6GAA
SCHEMBL4670853 0.77 HTR6 (0.36) NPSR1TSHRHTTHTR6GAA
SCHEMBL4670850 0.77 HTR6 (0.36) NPSR1TSHRHTTHTR6GAA
SCHEMBL4671860 0.76 ALDH1A1 (0.30) NPSR1TSHRHTTGAAALDH1A1
SCHEMBL4677102 0.74 NPSR1 (0.37) NPSR1TSHRHTTHTR6GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 NPSR1 937/4885TSHR 1614/4885HTT 1204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.